Who to call at Silexion Therapeutics Corp, and when
Fundz watches for the moments Silexion Therapeutics Corp starts buying, and tells you who to reach.
- An alert the day Silexion Therapeutics Corp raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Silexion Therapeutics Corp, from your own LinkedIn network
Silexion Therapeutics Corp
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
silexion.comAI Executive Summary
AI-powered analysis of 8-K filing content
Silexion Therapeutics announced positive preclinical findings for SIL204, a novel therapy targeting KRAS-driven cancers with a significant mechanism for systemic uptake, marking a critical milestone in the company's oncology pipeline development.
Key Takeaways
SIL204 demonstrates a key mechanism for endogenous systemic uptake in KRAS-driven cancers based on preclinical findings
This advancement represents a critical milestone in Silexion's research and development pipeline for oncology therapeutics
2 more takeaways
Related Filings (9)
9 more filings from Silexion Therapeutics Corp in the last 90 days
Filing Overview
What This Means
Silexion Therapeutics Corp filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.